Y Intercept Hong Kong Ltd Sells 26,750 Shares of Moderna, Inc. (NASDAQ:MRNA)

Y Intercept Hong Kong Ltd lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 26.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 74,409 shares of the company’s stock after selling 26,750 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Moderna were worth $3,094,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Blue Trust Inc. grew its holdings in Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after purchasing an additional 574 shares during the period. Raymond James & Associates lifted its position in shares of Moderna by 19.7% during the 3rd quarter. Raymond James & Associates now owns 162,074 shares of the company’s stock valued at $10,831,000 after buying an additional 26,657 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Moderna by 10,687.1% during the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after acquiring an additional 316,552 shares during the period. Assenagon Asset Management S.A. increased its holdings in Moderna by 79.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 13,159 shares of the company’s stock worth $879,000 after acquiring an additional 5,807 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Moderna by 22.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,234 shares of the company’s stock worth $6,656,000 after acquiring an additional 18,750 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Morgan Stanley dropped their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. Piper Sandler reiterated an “overweight” rating and issued a $69.00 price target (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Leerink Partners lowered their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Finally, Evercore ISI set a $50.00 target price on Moderna in a research report on Friday, February 14th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $60.63.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders sold 2,664 shares of company stock worth $115,210. Corporate insiders own 15.20% of the company’s stock.

Moderna Stock Down 4.6 %

Moderna stock opened at $33.90 on Tuesday. The company’s 50-day moving average price is $37.89 and its 200-day moving average price is $52.10. The company has a market cap of $13.05 billion, a PE ratio of -3.65 and a beta of 1.59. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.